Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.
Treating the itch associated with male pattern baldness, which is believed to be caused by DHT. Potential treatments discussed include salt water, finasteride, ketoconazole, and RU58841.
A user experiencing hair loss received three different diagnoses: androgenic alopecia, traction alopecia, and scarring alopecia, and tried treatments like minoxidil and finasteride without success. They are considering dutasteride but were advised to seek anti-inflammatory medication instead.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.
The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.
A user is seeking advice on increasing graft survivability after a hair transplant, mentioning PRP, Mesotherapy, Stem Cell injections, and considering L-Arginine before starting Minoxidil. They are looking for ways to support blood flow before applying Minoxidil.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
Seborrheic dermatitis can cause hair loss, and treatments like ketoconazole shampoo, topical steroids, and oral antifungals may help. Some consider using finasteride and minoxidil for hair loss despite dermatitis.
User asks about "The Ordinary - Multipeptide serum" for hair loss, containing Redensyl, Procapil, Capaxyl, Baicapil, and Anagain. Reply states it improves hair appearance but doesn't regrow hair.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Tretinoin can irritate seborrheic dermatitis, but using it with a moisturizer on calm skin may help. Parallel Health's skin microbiome testing and phage therapy are suggested for persistent issues.
The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.
Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
The post and conversation are about the user's high testosterone levels and their worsening hair loss despite trying various treatments. They are considering using low doses of anti-androgens to lower their testosterone levels as a potential solution.
A 48-year-old who had been thinning since 25 and reached NW4-5 baldness saw no improvement with 1mg/day finasteride and 5% minoxidil twice a day after 8 months. After copying another person's routine, they now use 0.5mg finasteride, ketoconazole shampoo weekly, daily microneedling with 0.5mm and 1mm once a week, and apply minoxidil twice daily, resulting in baby hairs on their bald spot and temples after three months.
The conversation is about a user making a homemade topical dutasteride solution to use alongside testosterone replacement therapy (TRT) and oral dutasteride. The user aims to reduce DHT locally at the testosterone injection site and on the scalp.
The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.
Topical finasteride can be effective for some, especially if oral finasteride causes side effects, but results may vary and can be slower. Combining topical finasteride with minoxidil is common, though some users switch to oral treatments for better results.
The conversation discusses the effectiveness and skepticism around topical dutasteride for hair loss, with mentions of combining it with other treatments like minoxidil and oral medications. Some users doubt its efficacy due to lack of independent studies and potential conflicts of interest.
Oral minoxidil may be more effective than topical due to uniform distribution and systemic activation, but can cause side effects like puffiness. Adding tretinoin to topical minoxidil can enhance its effectiveness by aiding conversion to its active form.
Finasteride users cannot donate blood due to potential risks to pregnant women, requiring a one-month cessation before donating. Dutasteride requires a six-month deferral, and topical applications are not restricted.